# OnCo record nct01436968 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct01436968/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct01436968", "NCT01436968" ;
  schema:name "Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer"@en ;
  schema:description "A phase 3 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct01436968/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01436968> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2011-09" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:drugs <https://onco.cc/drugs/aglatimagene-besadenovec/> ;
  onco:companies <https://onco.cc/companies/candel-therapeutics/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct01436968-lancet-oncol-2026/> .